Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank

European Journal of Preventive Cardiology · Published 2026-07-30 · DOI 10.1093/eurjpc/zwag400

Free full text

Authors (5)

Allan Sniderman, Karol Pencina, George Thanassoulis, Line Dufresne, Michael Pencina

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Sniderman, A., Pencina, K., Thanassoulis, G., et al. (2026). Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwag400

Related articles

• The role of lipoprotein (a) in premature cardiovascular disease: primed for prevention · European Journal of Preventive Cardiology · 2026 · Same journal
• Rheumatoid arthritis and risk of myocardial infarction: A nationwide cohort study · European Journal of Preventive Cardiology · 2026 · Same journal
• Beyond Survival: The Eriksen Case and the Dilemma of Elite Sport Participation After Sudden Cardiac Arrest · European Journal of Preventive Cardiology · 2026 · Same journal
• Cardiovascular prevention in childhood and young adults · European Journal of Preventive Cardiology · 2026 · Same journal
• Rethinking how we characterize the exercise blood pressure response in athletes · European Journal of Preventive Cardiology · 2026 · Same journal
• Navigating Clinical Likelihood and Cardiovascular Risk over a Lifetime Course of Coronary Artery Disease · European Journal of Preventive Cardiology · 2026 · Same journal
• Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention · European Journal of Preventive Cardiology · 2026 · Same journal
• Safe hearts need a healthy environment: prevention beyond our clinic walls · European Journal of Preventive Cardiology · 2026 · Same journal
• Multidisciplinary cardiac rehabilitation—an indispensable therapeutic intervention when starting a GLP-1 receptor agonist therapy? · European Journal of Preventive Cardiology · 2026 · Same journal
• Pharmacological risk stratification of Lp(a): diabetes status may refine residual cardiovascular risk beyond ASCVD history · European Journal of Preventive Cardiology · 2026 · Same journal